Table 3.
TRAEs occurring in ≥5% of all patients (any grade, safety population).
| All METex14 skipping NSCLC cohorts A + C (N = 255) | ||
|---|---|---|
| Category, n (%) | All grades | Grade 3–4 |
| Any AEa | 220 (86.3) | 62 (24.3) |
| Peripheral edema | 138 (54.1) | 19 (7.5) |
| Nausea | 51 (20.0) | 1 (0.4) |
| Diarrhea | 50 (19.6) | 1 (0.4) |
| Blood creatinine increased | 45 (17.6) | 1 (0.4) |
| Hypoalbuminemia | 37 (14.5) | 6 (2.4) |
| Alanine aminotransferase increased | 22 (8.6) | 5 (2.0) |
| Decreased appetite | 21 (8.2) | 1 (0.4) |
| Amylase increased | 19 (7.5) | 5 (2.0) |
| Fatigue | 18 (7.1) | 1 (0.4) |
| Alopecia | 18 (7.1) | 0 |
| Lipase increased | 17 (6.7) | 7 (2.7) |
| Pleural effusion | 16 (6.3) | 8 (3.1) |
| Edema | 16 (6.3) | 0 |
| Aspartate aminotransferase increased | 15 (5.9) | 3 (1.2) |
| Constipation | 15 (5.9) | 0 |
| Asthenia | 14 (5.5) | 1 (0.4) |
| Vomiting | 14 (5.5) | 1 (0.4) |
| Upper abdominal pain | 14 (5.5) | 0 |
aTwo patients had TRAEs that were fatal during the study; 1 patient had acute respiratory failure secondary to ILD, and 1 patient had severe worsening of dyspnea. Another patient had fatal acute hepatic failure after withdrawing consent to continue participating in the study.